Abstract
This was a single-blind 4-week parallel group comparative trial in fifty depressed patients. Twenty-five patients received 50 mg of Lentizol, a sustained-release form of amitriptyline, and twenty-five received 75 mg of Prothiaden. Both groups took their drugs as a single night-time dose.
Patient response was measured on a symptom check-list which was completed by the doctor and a self-rating depression scale. Tolerance was assessed by recording volunteered and observed side-effects and also by taking the pulse, blood pressure and an electrocardiogram before treatment and after 2 and 4 weeks.
A statistically better response was seen with Prothiaden at each follow-up assessment (1, 2 and 4 weeks) compared to Lentizol as measured by both the symptom check-list and the self-rating scale. Less side-effects were also seen with Prothiaden.
Minor changes were seen in the ECG records of two patients on Prothiaden and three on Lentizol. These changes were not associated with any clinical change in the patients' cardiovascular state. No consistent changes of any clinical significance were seen in the pulse and blood pressure recordings.
Get full access to this article
View all access options for this article.